Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million

Reuters03-26 16:31

Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million

Shanghai Bao Pharmaceuticals published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB49.2 million and a loss for the year of RMB395.3 million.
Revenue more than doubled to RMB49.2 million, driven mainly by RMB40.0 million of licensing revenue and RMB3.6 million from initial commercial sales of pharmaceutical products.
R&D expenses fell 1% to RMB248.2 million, reflecting lower share-based payment expenses, partly offset by higher trial and testing expenses and staff costs.
Administrative expenses decreased 2.8% to RMB104.6 million, which the company attributed mainly to reduced share-based payment expenses.
Cash and cash equivalents rose to RMB1.24 billion and total equity increased to RMB1.59 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068628), on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622837126?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 16:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622837126","market":"us","top_or_hot":-1,"title":"Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Shanghai Bao Pharmaceuticals published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB49.2 million and a loss for the year of RMB395.3 million.\n        </li>\n<li>\n          Revenue more than doubled to RMB49.2 million, driven mainly by RMB40.0 million of licensing revenue and RMB3.6 million from initial commercial sales of pharmaceutical products.\n        </li>\n<li>\n          R&amp;D expenses fell 1% to RMB248.2 million, reflecting lower share-based payment expenses, partly offset by higher trial and testing expenses and staff costs.\n        </li>\n<li>\n          Administrative expenses decreased 2.8% to RMB104.6 million, which the company attributed mainly to reduced share-based payment expenses.\n        </li>\n<li>\n          Cash and cash equivalents rose to RMB1.24 billion and total equity increased to RMB1.59 billion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068628), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 16:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Shanghai Bao Pharmaceuticals published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB49.2 million and a loss for the year of RMB395.3 million.\n        </li>\n<li>\n          Revenue more than doubled to RMB49.2 million, driven mainly by RMB40.0 million of licensing revenue and RMB3.6 million from initial commercial sales of pharmaceutical products.\n        </li>\n<li>\n          R&amp;D expenses fell 1% to RMB248.2 million, reflecting lower share-based payment expenses, partly offset by higher trial and testing expenses and staff costs.\n        </li>\n<li>\n          Administrative expenses decreased 2.8% to RMB104.6 million, which the company attributed mainly to reduced share-based payment expenses.\n        </li>\n<li>\n          Cash and cash equivalents rose to RMB1.24 billion and total equity increased to RMB1.59 billion.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068628), on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL6F9KCn:1","article_id":"2622837126","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622837126","pubTimestamp":1774513891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Bao Pharmaceuticals published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB49.2 million and a loss for the year of RMB395.3 million.Revenue more than doubled to RMB49.2 million, driven mainly by RMB40.0 million of licensing revenue and RMB3.6 million from initial commercial sales of pharmaceutical products.R&D expenses fell 1% to RMB248.2 million, reflecting lower share-based payment expenses, partly offset by higher trial and testing expenses and staff costs.Administrative expenses decreased 2.8% to RMB104.6 million, which the company attributed mainly to reduced share-based payment expenses.Cash and cash equivalents rose to RMB1.24 billion and total equity increased to RMB1.59 billion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B","BK1161":"生物科技"},"translate_title":"上海宝药业2025财年收入跃升至人民币4900万元；经营亏损扩大至人民币3.95亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":0.9},"content_text":"Shanghai Bao Pharmaceuticals FY2025 revenue jumps to RMB49 million; operating loss widens to RMB395 million\n    \n\n\n          Shanghai Bao Pharmaceuticals published an annual results announcement for the year ended Dec. 31, 2025, reporting revenue of RMB49.2 million and a loss for the year of RMB395.3 million.\n        \n\n          Revenue more than doubled to RMB49.2 million, driven mainly by RMB40.0 million of licensing revenue and RMB3.6 million from initial commercial sales of pharmaceutical products.\n        \n\n          R&D expenses fell 1% to RMB248.2 million, reflecting lower share-based payment expenses, partly offset by higher trial and testing expenses and staff costs.\n        \n\n          Administrative expenses decreased 2.8% to RMB104.6 million, which the company attributed mainly to reduced share-based payment expenses.\n        \n\n          Cash and cash equivalents rose to RMB1.24 billion and total equity increased to RMB1.59 billion.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Bao Pharmaceuticals Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12068628), on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622837126","isCrawlerRequest":true}